doi: 10.14202/vetworld.2017.1286-1291
Share this article on [Facebook] [LinkedIn]
Article history: Received: 07-06-2017, Accepted: 21-09-2017, Published online: 31-10-2017
Corresponding author: N. Kavya
E-mail: kavyavetico@gmail.com
Citation: Kavya N, Rao S, Sathyanarayana ML, Narayanaswamy HD, Byregowda SM, Ranganath L, Kamaran A, Purushotham KM, Kishore TK (2017) Survivin expression in canine spontaneous cutaneous and subcutaneous tumors and its prognostic importance, Veterinary World, 10(10): 1286-1291.Aim: The present study was carried out to know the expression level of survivin, an inhibitor of apoptosis protein with an objective to determine its prognostic importance in cutaneous and subcutaneous tissue tumors of dogs.
Materials and Methods: Forty cases of canine cutaneous and subcutaneous tissue tumors on histopathological examination revealed various round cell, epithelial, and mesenchymal cell tumors. Survivin gene expression was detected in all tumors tested by TaqMan real-time polymerase chain reaction assay by comparative cycle threshold method.
Results: The mean survivin gene expression value of benign tumors was 0.94±0.63 folds and that of malignant tumors was 18.87±5.30 folds. Postsurgical follow up of 30 malignant tumor cases revealed death in 8, recurrence in 7, and neoplastic free alive status in 15 dogs with mean survivin fold difference values of 48.49±12.39, 14.63±6.37, and 5.034±2.27, respectively. The mean survivin gene expression value was significantly higher in malignant (30 cases, 18.87±5.30) compared to benign tumors (10 cases, 0.94±0.63), and it varied between various postsurgical follow-up groups (p<0.05). Survival analysis, using survivin gene expression median cutoff value of 3.74 in 30 malignant tumors, was performed to predict probable survival period in malignant cutaneous and subcutaneous tumors of dogs.
Conclusion: Results of the present study indicated that the expression of survivin in canine cutaneous and subcutaneous tumors has prognostic value, and survivin expression greater than median cutoff value of 3.74 has a poor prognosis.
Keywords: cutaneous and subcutaneous tumors, prognostic value, quantitative real-time polymerase chain reaction, survivin.
1. Mobahat, M., Narendran, A. and Riabowol, K. (2014) Survivin as a preferential target for cancer therapy. Int. J. Mol. Sci., 15: 2494-2516. [Crossref] [PubMed] [PMC]
2. Jemal, A., Seigel, R., Ward, E., Hao, Y., Xu, J., Murray, T. and Thun, M.J. (2008) Cancer statistic. Cancer J. Clin., 58: 71-96. [Crossref] [PubMed]
3. Murphy, S., Sparkes, A.H., Blunden, A.S., Brearley, M.J. and Smith, K.C. (2006) Effects of stage and number of tumours on prognosis of dogs with cutaneous mast cell tumours. Vet. Record, 158(9): 287-291. [Crossref]
4. Chikweto, A., Mcneil, P., Bhaiyat, M.I., Stone, D. and Sharma, R.N. (2011) Neoplastic and nonneoplastic cutaneous tumours of dogs in Grenada, West Indies. Int. Sch. Res. Netw., 2011: 6.
5. Dayananda, T.S., Rao, S., Byregowda, S.M., Satyanarayana, M.L., Jayachandra, K.C. and Shilpa, V.T. (2009) Proliferation index in hemangioma and hemangiosarcoma of dogs. Indian Vet. J., 86: 454-456.
6. Jayachandra, K.C., Rao, S., Byregowda, S.M., Satyanarayana, M.L., Dayananda, T.S. and Shilpa, V.T. (2011) Pathology of mammary gland tumours in canines. Indian Vet. J., 88(1): 74-75.
7. Mukaratirwa, S., Chipunza, J. and Chitanga, S. (2005) Canine cutaneous neoplasms: Prevalence and influence of age, sex and site on the presence and potential malignancy of cutaneous neoplasms in dogs from Zimbabwe. J. S. Afr. Vet. Assoc., 76: 59-62. [Crossref]
8. Pawan, K. (2008) Studies on Pathology and Evaluation of Expression of C-erbB2 Inspontaneous Canine Mammary Tumours. M.V.Sc Thesis. Izatnagar: Indian Veterinary Research Institute.
9. Chiti, L. and Amber, E.I. (1992) Incidence of tumours seen at the faculty of veterinary medicine, university of Zambia: A four year retrospective study. Zimbabwe Vet. J., 3: 143-147.
10. Shakir, S.A. and Sundararaj, A. (1994) Skin neoplasms of dogs in madras city. Indian J. Vet. Pathol., 18: 154-158.
11. Martins, A.M., Elia, T. and Jose, L.G. (2002) Retrospective review and systemic study of mammary tumours in dogs and characteristics of the extracellular matrix. Braz. J. Vet. Res. Anim. Sci., 39(1): 38-42. [Crossref]
12. Sorenmo, K.U., Shofer, F.S. and Goldschmidt, M.H. (2000) Effect of spaying and timing of spaying on survival of dogs with mammary carcinoma. J. Vet. Intern. Med., 14: 266-270. [Crossref] [PubMed]
13. Donnay, I., Rauis, J., Devleeschouwer, N., Wouters, B., Leclerc, G. and Verstegen, J. (1995) Comparison of estrogen and progesterone receptor expression in normal and tumour mammary tissues from dogs. Am. J. Vet. Res., 56(9): 1188-1194. [PubMed]
14. Salvesen, G.S. and Duckett, C.S. (2002) IAP proteins: Blocking the road to death's door. Nat. Rev. Mol. Cell Biol., 3: 401-410. [Crossref] [PubMed]
15. Altieri, D.C. and Marchisio, C. (1999) Survivin apoptosis: An interloper between cell death and cell proliferation in cancer. Lab. Invest., 79(11): 1327-1333. [PubMed]
16. Adida, C., Berrebi, D., Peuchmaur, M., Mugica, R.M. and Altieri, D.C. (1998) Antiapoptosis gene, survivin, and prognosis of neuroblastoma. Lancet, 351: 882-883. [Crossref]
17. Boidot, R., Vegran, F., Jacob, D., Chevrier, S., Gangneux, N., Taboureau, J. and Oudin, C., Rainville, V., Mercier, L., Lizard-Nacol, S. (2008) The expression of BIRC5 is correlated with loss of specific chromosomal regions in breast carcinomas. Genes Chromosomes Cancer, 47: 299-308. [Crossref] [PubMed]
18. Bongiovanni, L., Romanucci, M., Malatesta, D., Andrea, A.D., Ciccarelli, A. and Della Salda, L. (2014) Survivin and related proteins in canine mammary tumours: Immunohistochemical expression. Vet. Pathol., 134: 1-7.
19. Upadhyay, R., Khurana, R., Kumar, S., Ghoshal, U.C. and Mittal, B. (2011) Role of survivin gene promoter polymorphism (-31G>C) in susceptibility and survival of esophageal cancer in northern India. Ann. Surg. Oncol., 18: 880-887. [Crossref] [PubMed]
20. Yang, L., Zhu, H., Zhou, B., Gu, H., Yan, H., Tang, N., Dong, H., Sun, Q., Cong, R., Chen, G. and Wang, B. (2009) The association between the survivin C-31G polymorphism and gastric cancer risk in a Chinese population. Dig. Dis. Sci., 54: 1021-1028. [Crossref] [PubMed]
21. Borges, B.N., Burbano, R.R. and Harada, M.L. (2011) Survivin-66 31C/G polymorphism and gastric cancer risk in a Brazilian population. Clin. Exp. Med., 11: 189-193. [Crossref] [PubMed]
22. Dimitrakopoulos, F.I., Marousi, S., Antonacopoulou, A.G., Floratou, K., Bravou, V., Kottorou, A., Stavropoulos, M., Koutras, A.K., Scopa, C.D. and Kalofonos, H.P. (2011) The survivin-31 snp in human colorectal cancer correlates with survivin splice variant expression and improved overall survival. Cell Oncol., 34: 381-391. [Crossref] [PubMed]
23. Theodoropoulos, G.E., Michalopoulos, N.V., Panoussopoulos, S.G., Taka, S. and Gazouli, M. (2010) Effects of caspase-9 and survivin gene polymorphisms in pancreatic cancer risk and tumour characteristics. Pancreas, 39: 976-980. [Crossref] [PubMed]
24. Kawata, N., Tsuchiya, N., Horikawa, Y., Inoue, T., Tsuruta, H., Maita, S., Satoh, S., Mitobe, Y., Narita, S. and Habuchi, T. (2011) Two survivin polymorphisms are cooperatively associated with bladder cancer susceptibility. Int. J. Cancer, 129: 1872-1880. [Crossref] [PubMed]
25. Qin, C., Cao, Q., Li, P., Ju, X., Wang, M., Chen, J., Liu, N., Yin, Y. and You, Y. (2012) Functional promoter-31G>C variant in survivin gene is associated with risk and progression of renal cell cancer in a Chinese population. PLoS One, 7: 288-289. [Crossref]
26. Kostic, M., Nikolic, N., Ilic, B., Carkic, J., Milenkovic, S. and Vukadinovic, M. (2013) Analysis of polymorphism in the survivin gene promoter as a potential risk factor for head and neck cancers development. Srp. Arh. Celok. Lek., 141: 304-307. [Crossref] [PubMed]
27. Lauxen, I., Oliveira, M.G., Rados, P.V., Lingen, M.W., Nor, J.F. and Sant'anaFilho, M. (2014) Immunoprofiling of oral squamous cell carcinomas reveals high p63 and survivin expression. Oral Dis., 20: 76-80. [Crossref] [PubMed]
28. Brundage, M.D., Davies, D. and Mackillop, W.J. (2002) Prognostic factors in non-small cell lung cancer; A decade of progress. Chest, 122: 1037-1057. [Crossref] [PubMed]
29. Li, J., Zhang, Z., Dai, Z., Anthony, P.P., Christoph, P., Carl, M., Yian, W. and Ming, Y. (2003) RASSF1 a promoter methylation and kras2 mutations in non-small cell lung cancer. Neoplasia., 5: 362-366. [Crossref]
30. Uchide, T., Takatsu, N., Fujimori, Y., Fukushima, U. and Itoh, H. (2005) Expression of survivin mRNA in dog tumours. DNA Sequence, 16: 329-334. [Crossref] [PubMed]
31. Altieri, D.C. (2008) Survivin, cancer networks and pathway-directed drug discovery. Nat. Rev. Cancer, 8: 61-70. [Crossref] [PubMed]
32. Jaiswal, P.K., Goel, A. and Mittal, R.D. (2015) Survivin: A molecular biomarker in cancer. Indian J. Med. Res., 141: 389-397. [Crossref] [PubMed] [PMC]
33. Renn, D.F.U., Daiki, K., Watabe, A.I., Yoshifumi, E. and Tsuyoshi, K. (2014) Prognostic utility of apoptosis index, Ki-67 and survivin expression in dogs with nasal carcinoma treated with orthovoltage radiation therapy. J. Vet. Med. Sci., 76(11): 1505-1512. [Crossref] [PMC]
34. Elsheikh, S.M., Omar, T.A., Abdel, H.H.S. and Abdelsattar, M.F. (2014) Expression of the antiapoptotic survivin in the adenomatoid odontogenic tumours. Tanta Dent. J., 11: 174-179.
35. Shoeneman, J.K., Ehrhart, E.J., Eickhoff, J.C., Charles, J.B., Powers, B.E. and Thamm, D.H. (2011) Expression and function of survivin in canine osteosarcoma. Cancer Res., 72: 249-259. [Crossref] [PubMed]
36. Wimmershoff, J., Polkinghorne, A., Grest, P., Schade, B., Marchal, T., Keller, S.M. and Guscetti F. (2010) Immunohistochemical Detection of survivin in canine lymphoma. J. Comp. Pathol., 142: 311-322. [Crossref] [PubMed]
37. Lechler, P., Renkawitz, T., Campean, V., Balakrishnan, S., Tingart, M., Grifka J. and Schaumburger J. (2011) The antiapoptotic gene survivin is highly expressed in human chondrosarcoma and promotes drug resistance in chondrosarcoma cells in vitro. BMC Cancer, 11: 120. [Crossref] [PubMed] [PMC]